TWI808648B - 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 - Google Patents

使用包含gdc-9545及gdc-0077之組合療法治療乳癌 Download PDF

Info

Publication number
TWI808648B
TWI808648B TW111105232A TW111105232A TWI808648B TW I808648 B TWI808648 B TW I808648B TW 111105232 A TW111105232 A TW 111105232A TW 111105232 A TW111105232 A TW 111105232A TW I808648 B TWI808648 B TW I808648B
Authority
TW
Taiwan
Prior art keywords
gdc
patient
combination
use according
acceptable salt
Prior art date
Application number
TW111105232A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237100A (zh
Inventor
席亞拉 梅特卡夫
曉均 王
周維
Original Assignee
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI808648(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商建南德克公司 filed Critical 美商建南德克公司
Publication of TW202237100A publication Critical patent/TW202237100A/zh
Application granted granted Critical
Publication of TWI808648B publication Critical patent/TWI808648B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111105232A 2021-02-16 2022-02-14 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 TWI808648B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
US63/149,944 2021-02-16

Publications (2)

Publication Number Publication Date
TW202237100A TW202237100A (zh) 2022-10-01
TWI808648B true TWI808648B (zh) 2023-07-11

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105232A TWI808648B (zh) 2021-02-16 2022-02-14 使用包含gdc-9545及gdc-0077之組合療法治療乳癌

Country Status (8)

Country Link
US (1) US20230381155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294395B1 (cg-RX-API-DMAC7.html)
JP (1) JP7904849B2 (cg-RX-API-DMAC7.html)
CN (1) CN117377472A (cg-RX-API-DMAC7.html)
ES (1) ES3030540T3 (cg-RX-API-DMAC7.html)
PL (1) PL4294395T3 (cg-RX-API-DMAC7.html)
TW (1) TWI808648B (cg-RX-API-DMAC7.html)
WO (1) WO2022177844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538147A (ja) * 2022-11-02 2025-11-26 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216280A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
WO2020037203A2 (en) * 2018-08-17 2020-02-20 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216280A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
WO2020037203A2 (en) * 2018-08-17 2020-02-20 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer

Also Published As

Publication number Publication date
JP2024506385A (ja) 2024-02-13
WO2022177844A1 (en) 2022-08-25
EP4294395A1 (en) 2023-12-27
CN117377472A (zh) 2024-01-09
PL4294395T3 (pl) 2025-06-23
JP7904849B2 (ja) 2026-08-13
ES3030540T3 (en) 2025-06-30
EP4294395C0 (en) 2025-03-26
US20230381155A1 (en) 2023-11-30
EP4294395B1 (en) 2025-03-26
TW202237100A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
JP7667132B2 (ja) Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20230381155A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
US20240173306A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
TWI881203B (zh) 使用包含gdc-9545及帕他色替之組合療法治療乳癌
KR20070034510A (ko) Src 키나아제 억제제 azd0530 및 항에스트로겐 약물또는 egfr-tk-억제제를 포함하는 조합 생성물
TWI828060B (zh) 使用包含gdc-9545及阿貝西尼或瑞博西尼之組合療法治療乳癌
HK40101173A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
HK40129153A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40101825A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib
HK40084792B (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40098151A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40066922A (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant